Surgery for pharmacoresistant epilepsy in the developing world: A pilot study

Area of Science:

• Global health
• Neurology
• Surgical innovation

Background:

• Epilepsy prevalence is significantly higher in developing countries compared to developed nations.
• Pharmacotherapy is ineffective for many individuals with epilepsy, making surgery a crucial treatment option.
• Low-resource settings present unique challenges for advanced medical interventions like epilepsy surgery.

Purpose of the Study:

• To establish and evaluate a sustainable model for surgical treatment of intractable temporal lobe epilepsy (iTLE) in a low-resource environment in Uganda.
• To assess the feasibility and outcomes of epilepsy surgery within the constraints of a developing country.
• To demonstrate the potential for successful surgical intervention for pharmacoresistant epilepsy in underserved regions.

Main Methods:

• Development of a specialized epilepsy treatment center in Uganda, CURE Children's' Hospital of Uganda (CCHU).
• Partnership with international epilepsy professionals and training of local healthcare staff.
• Prescreening of patients for iTLE at regional clinics, followed by video-electroencephalography (EEG), computed tomography (CT) imaging, and neuropsychological evaluation at CCHU.
• Remote data analysis and treatment recommendations by epilepsy experts.

Main Results:

• Ten patients diagnosed with iTLE were surgically treated at CCHU.
• Sixty percent (6 out of 10) of the patients achieved seizure freedom post-surgery.
• No instances of neurological morbidity or mortality were reported among the treated patients.

Conclusions:

• The developed model for surgical treatment of pharmacoresistant temporal lobe epilepsy is effective and functional in a low-resource, developing world setting.
• This approach highlights the success of collaborative efforts and local staff training in overcoming resource limitations for complex surgical procedures.
• The study provides a viable blueprint for expanding access to life-changing epilepsy surgery in underserved global populations.